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Secondary transporters use alternating access mechanisms to couple uphill substrate movement 
to downhill flux of a coupling ion, presenting binding sites alternately to either side of the membrane. 
Most known transporters utilize a “rocking bundle” motion, where the protein moves around an 
immobile substrate binding site to regulate ingress. However, one protein, the glutamate transporter 
homolog GltPh translocates its entire substrate binding site vertically across the width of the membrane, 
a so-called “elevator” mechanism. Here we examine an unrelated transporter, the Na+/succinate 
transporter VcINDY. With the crystal structure of an inward facing state of VcINDY as a template, we used 
the “repeat swap” approach to computationally predict the structure of the outward-facing state of the 
transporter. Our model suggests that VcINDY undergoes a substantial elevator-like movement to transfer 
its substrate binding site, with a vertical translation of ~15 Å and a rotation of 43o. Crosslinks formed 
between three different pairs of introduced cysteine residues, proximate only in the outward-facing 
state, confirm this large-scale motion. These crosslinks completely inhibit transport, demonstrating that 
such movement is essential for transport. In contrast, multiple crosslinks across the VcINDY dimer 






Secondary active transporters constitute a large class of proteins responsible for catalyzing the 
passage of key compounds across the lipid bilayer in all living cells. These molecular machines harness 
the energy supplied by the electrochemical gradient of one solute, usually a coupling ion like H+ or Na+, 
to power the transport of another solute against its concentration gradient. Secondary transporters 
operate by an alternating access mechanism in which conformational changes in the protein alternately 
expose the substrate-binding site to either side of the membrane. A minimum of two conformational 
states are therefore required to achieve alternating access; an inward-facing state, where the substrate is 
accessible to the cytoplasmic side of the membrane only, and an outward-facing state, where the 
substrate is only accessible to the extracellular side1,2. Many transporters also utilize intermediate 
“occluded” states in which the substrate-binding site is accessible to neither side of the membrane3,4. 
The ever-growing collection of secondary transporter crystal structures reveals a remarkable 
diversity of protein folds; structural and functional investigations have begun to illuminate the 
conformational mechanisms by which these folds achieve alternating access. Of the 17 secondary 
transporter folds reported to date, the Major Facilitator Superfamily (MFS) fold and the LeuT fold 
represent a majority of the known protein sequences and an overwhelming majority of the known X-ray 
crystal structures5,6. In both cases, their conformational mechanisms involve movement of helices around 
a substrate binding site, which is usually situated at the center of the lipid bilayer. While the overall 
mechanism has been described as movements of domains in “rocking bundle” or “rocker-switch” type 
conformational changes, the available evidence also suggests a role for individual “gating” helices that 
help determine intermediate steps in the transport cycle7-11. Either way, for both of these large families, 
the substrate retains its relative position in the membrane regardless of the conformation of the 
transporter. 
A dramatically different route to achieving alternating access involves an elevator-type (or 
“carrier”) mechanism; here, the substrate-binding site itself is moved. Elevator-type transporters are 
composed of two domains; a scaffold domain that remains relatively rigid during the transport cycle, and 
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a second domain that contains all the residues necessary to bind the substrate, referred to as the 
transport domain. This mechanism derives its name from the elevator-like rigid body translation of the 
transport domain back and forth across the hydrophobic barrier provided by the protein and lipid bilayer 
by moving the entirety of the substrate-binding site and allowing the substrate to be alternately 
exposed to both sides of the membrane. To date, only the glutamate transporter homolog GltPh has been 
convincingly shown to employ an elevator mechanism12,13. GltPh belongs to a relatively small family of 
proteins (the dicarboxylate/amino acid:cation symporters, DAACS; transporter classification database 
(TCDB) family 2.A.23), raising the possibility that its mechanism is unique to this small family. However, a 
similar mechanism has recently been hypothesized for the Na+/H+ antiporters, though this proposal 
remains controversial14. Thus, the prevalence of elevator-like mechanisms in biology remains a 
compelling and unanswered puzzle. 
Here, using structural modeling combined with extensive disulfide crosslinking, biochemical, and 
functional characterization of purified VcINDY, we report that the Na+/succinate transporter VcINDY also 
employs an elevator-type mechanism. VcINDY, from Vibrio cholerae, belongs to the divalent anion 
sodium symporter (DASS) family of transporters (TDCB family 2.A.47), which also contains members of 
the SLC13 family responsible for the uptake of citrate, Krebs cycle intermediates, and sulfate, in 
humans15-17. VcINDY is the only DASS family member for which a high-resolution structure is known; this 
structure represents a unique fold in the Protein Databank18. The 3.2 Å structure of VcINDY reveals a 
dimeric architecture; the positioning of the bound ligand, in this case citrate, indicates that this structure 
reflects an inward-facing state of this transporter. Each protomer consists of 11 transmembrane (TM) 
helices that can be partitioned into two distinct domains; a scaffold domain that forms all inter-protomer 
contacts and a transport domain that houses the substrate binding site (Fig. 1 and 2) – an arrangement 
highly reminiscent of GltPh.  
The results presented here computationally predict and experimentally confirm an outward-
facing state of VcINDY, and indicate that a ~15 Å translation accompanied by a 43o rigid body rotation of 
the transport domain occurs to expose the substrate binding site to the external solution. This work 
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therefore reveals a second transporter family, with a different fold than GltPh, that employs an elevator-
type mechanism with similarities to that of GltPh, but also with key differences. Given the relationship 
between VcINDY and other families in the large “Ion Transporter (IT) Superfamily” we raise the possibility 
that this superfamily shares key features of the elevator mechanism and that, like the rocking bundle-
type mechanisms, this conformational strategy is also widespread in secondary transport19,20. 
 
Results 
VcINDY contains inverted-topology structural repeats 
The only structural information available for VcINDY corresponds to the substrate-bound, inward-
facing state of the transporter18. Transporters are exceedingly dynamic proteins that need to fluctuate 
between multiple conformational states to function; so, while informative, a structure of a single 
conformational state reveals very little about the actual mechanism of transport. We sought to explore 
additional conformations of VcINDY using computational modeling, taking advantage of pseudo-
symmetrical repeats apparent from the crystal structure18. In this procedure, called repeat-swap 
homology modeling, we identify repeating structural units by careful analysis of the crystal structure; we 
then swap the conformations of these repeating units21. Underlying the success of this procedure is the 
fact that the structures of these repeating units are not perfectly symmetric; it is the subtle 
conformational differences between the repeating units that lead to the prediction of alternate 
conformational states upon interconversion. Repeat-swap homology modeling has been applied to 
several transporter families and found to produce accurate predictions of even dramatically different 
conformations12,21-23.   
VcINDY contains an, an inverted-topology structural repeat related by pseudo two-fold symmetry 
around the axis in the plane of the membrane18; repeat unit 1 (RU1) consisting of TM helices 2-6 (defined 
here as residues 42-242) and repeat unit 2 (RU2) consisting of TM helices 7-11 (residues 260-453; Fig. 1a 
and b, RU1: blue and cyan helices, RU2: red and orange helices). TM1 is a peripheral helix in VcINDY and 
is not part of either repeating unit. Our alignments of the amino acid sequences of RU1 and RU2 revealed 
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a low sequence identity of ~20% (Supplementary Fig. 1a). However, upon superimposition of the 
repeating units, we clearly see that they share a similar architecture, with a root mean square deviation 
(RMSD) value for the CD atoms of ~4.3 Å when the whole repeat is superimposed (Fig. 1c). When we 
divided up the repeats so that we compared only the helices in each repeat comprising the transport 
domain (blue/red) or only the helices in each repeat comprising the scaffold domain (cyan/orange), we 
found much higher structural similarity (RMSD values of 2.0-2.1 Å). This result suggests that the main 
contribution to the structural differences between the repeats comes from the orientation of the 
transport domain helices relative to the scaffold domain helices (Fig. 1c). Repeating the comparisons 
using template modeling scores (TM-scores), which give a measure of structural similarity that is 
independent of segment length (values between 0 and 1; 1 being structurally identical), underscores this 
observation. Specifically, superimposing the entirety of each repeat gave a TM-score of 0.52, which 
increased to 0.78 and 0.83 when comparing only the transport and scaffold domain helices, respectively. 
 
The inward-facing state structure of VcINDY can be used to predict an alternate conformation 
We applied the repeat-swap procedure to VcINDY by modeling the conformation of RU1 using 
RU2 as a template, and vice versa (Supplementary Fig. S1b). The resulting model revealed a substantial 
conformational change compared to the inward-facing crystal structure (Fig. 2b). As a result of this 
conformational change, which is localized to the transport domain, the substrate binding site is exposed 
to the extracellular side of the membrane, clearly demonstrating that the repeat-swapped model 
represents a putative outward-facing state of VcINDY (Fig. 2c and Supplementary Fig. 2a and b).   
To analyze the conformational changes that occur during the transformation from the inward- to 
the outward-facing conformation, we superimposed the model onto the structure using only helices 
from the oligomerization interface, which also allowed us to construct a model of the dimer (Fig. 2b). We 
note that this model is therefore based on the assumption that the dimer interface is unchanged during 
transport (an assumption we test explicitly below). This comparison predicts that the entire transport 
domain would undergo a ~15 Å vertical translation accompanied by a 43o rotation (Supplementary Fig. 
7 
S2a). As a consequence, transport domain residues would be displaced by 10-20 Å (Supplementary Fig. 
S2b). 
 
Design of site-specific cysteine pairs to test the outward-facing model 
A key prediction of the outward-facing repeat-swapped model is that transport requires a major 
translocation of the transport domain across the membrane, accompanied by a significant rotation. If 
such a motion indeed occurs, then there should be residues that are far apart in one state, but that are 
brought into close proximity in the other state. To test this idea, we introduced pairs of cysteine residues 
at positions that are widely separated in the inward-facing structure (CE-CE distance >12 Å), but are 
brought closely enough together (CE-CE distance <7 Å) in the predicted outward-facing state that they 
could potentially form disulfide links. The ready formation of crosslinks in these proteins would strongly 
support the proposed conformational change. We also predict that, by confining the protein to a single 
state in the transport cycle, these crosslinks should strongly inhibit transport. To validate this approach, 
we also designed a cysteine pair that should selectively stabilize the known inward-facing state by 
substituting residues that are distant in the outward-facing model, but in close proximity in the inward-
facing crystal structure. 
As a starting construct for our experiments we used a mutant in which we substituted serine 
residues for the three native cysteines in VcINDY, giving us a cysteine-free background (Cysless), which is 
stable and, aside from having a ~4-fold lower transport rate (Supplementary Fig. 3a), is functionally 
equivalent to wild type VcINDY at catalyzing Na+-driven succinate uptake.  
In total, we introduced 24 different combinations of double cysteine mutants into the interface 
between the transport and scaffold domains. However, most of these mutant combinations resulted in 
unstable protein that expressed poorly or aggregated (data not shown). The majority of these cysteine 
substitutions were located towards the center of the transport domain in positions with low solvent 
accessibility. Only one of the “buried” interfacial pairs that we tested, T154C/V272C, yielded stable 
protein and was used in further studies (Fig. 2b). The distance between the CE-CE atoms of T154 (from 
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HP1) and V272 (from TM7) in the inward-facing structure (difs) = 18.7 Å, whereas in the outward-facing 
model the distance (dofm) = 3.9 Å. We subsequently targeted regions at the periphery of the interface, in 
particular the symmetry related helices 4c and 9c. Solvent accessible loops were more tolerant to 
modification so we were able to introduce two cysteine pairs, A120C/V165C in helix 4c/HP1 (difs = 11.7 Å; 
dofm = 4.7 Å), and A346C/V364C in helix 9c/HP2 (difs = 16 Å; dofm = 5.6 Å), with no apparent reduction in 
protein stability (Fig. 2b). Together, these cysteine pairs occupy three different positions at the interface 
between the transport and scaffold domains, providing good coverage of the conformational change 
predicted by our model. To stabilize the inward-facing state, we introduced the double cysteine mutant 
L60C/S381C in TM2/HP2 (difs = 6.9 Å; dofs = 20.6 Å, Supplementary Fig. 5a). All four cysteine pairs were well 
tolerated by VcINDY under reducing conditions, as each purified mutant produced a single symmetrical 
peak upon size exclusion chromatography (SEC), and demonstrated robust transport activity 
(Supplementary Fig. 3b).  
 
Cysteine crosslinking supports the outward-facing model 
In some experiments we generated crosslinks using HgCl2, which can act as a homobifunctional 
crosslinking reagent, in others we used oxidizing agent copper phenanthroline (CuPhen) to catalyze 
disulfide bond formation. We screened for successful crosslinks using the gel-shift assay described by 
Basilio et al24. Specifically, after treatment with crosslinking reagent, we enumerated the remaining free 
cysteines by treating the protein with a 5 kDa PEG-maleimide (mPEG5K), which causes a substantial shift 
in the protein’s gel mobility upon reaction with free cysteine. If the introduced cysteines are crosslinked 
with each other, however, then they will be unable to react with mPEG5K and the protein band will run 
as monomeric VcINDY on SDS-PAGE. Before crosslinking, each double cysteine mutant was almost 
completely PEGylated after incubation with mPEG5K, demonstrating that both cysteines in each mutant 
were accessible to the probe (Fig. 3 and Supplementary Fig. 5b). In contrast, after treatment with HgCl2 
or CuPhen all three outward-stabilizing double cysteine mutants and the single inward-stabilizing 
mutant were completely protected from PEGylation (Fig. 3 and Supplementary Fig. 4, 5b), suggesting 
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that all four cysteine pairs successfully formed intramolecular crosslinks. Treatment of the double 
cysteine mutants with crosslinking reagents did not significantly affect the elution volume of the protein 
peak on SEC, but did result in slight peak broadening; we observed minimal aggregation for these 
proteins (data not shown). These results indicate that treatment with crosslinking reagent is well 
tolerated and that the fold of the crosslinked protein is not disrupted. 
To obtain direct physical evidence of crosslink formation we analyzed the double cysteine mutants using 
liquid chromatography-tandem mass spectrometry (LC-MS/MS, Fig. 4). If we indeed formed crosslinks in 
the cysteine mutants then we should be able to directly detect the crosslinked peptides using this 
approach. For these experiments we used only CuPhen to crosslink because of concerns about adding 
the toxic metal Hg2+ to the Mass Spectrometer and because of uncertainty regarding whether Hg2+-
mediated crosslinks contain a metal bridge or only a disulfide24. After incubating the cysteine mutants 
with either CuPhen or DTT (to prevent spontaneous crosslink formation) we digested the proteins, 
separated the proteolytic fragments by liquid chromatography, and Mass Spec, unambiguously 
assigning all the peptides produced (Fig. 4). Upon interrogation of the LC-MS/MS output for specific 
peptides we identified disulfide-crosslinked peptides in the CuPhen-treated samples of both 
A120C/V165C and T154C/V272C; these peptides were completely absent in the reduced protein samples 
(Fig. 4a and b, right panel). We also obtained LC-MS/MS data consistent with crosslink formation 
between A346C and V364C. However, an insufficient number of proteolytic sites between residues 360 
and 390 prevented us from confidently assigning the MS fragment peaks (data not shown). Due to this 
technical limitation, we were also unable to obtain consistent LC-MS/MS data for the inward-stabilizing 
mutant L60C/S381C. These data unequivocally demonstrate crosslink formation between two of the 
introduced cysteine pairs, and strongly suggest that the mPEG5K labeling results for the other two pairs 
indeed reflect crosslink formation. Formation of these crosslinks strongly supports our prediction that 
the outward facing conformation of VcINDY requires a specific, large excursion of the transport domain. 
(Supplementary Movie 2).  
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Crosslinking VcINDY abolishes transport activity 
Our hypothesis for the VcINDY transport mechanism, based on the model of the outward-facing 
conformation, is that the translocation of the transport domain is essential for transport, physically 
moving the binding site from one side of the membrane to the other (Fig. 2 and Supplementary Movie 
1). If true, then crosslinking VcINDY in either the inward- or outward-facing state should straightjacket 
the transporter and curtail its transport activity. We tested this prediction by reconstituting the double 
cysteine mutants into proteoliposomes and measuring succinate transport activity in the presence and 
absence of a disulfide link (Fig. 5). Indeed, when we form crosslinks by treating proteoliposomes 
containing double cysteine mutants with excess HgCl2 (on both sides of the membrane) we observed 
almost complete cessation of succinate transport activity for all three outward-stabilizing double 
cysteine mutants (Fig. 5). Transport activity was almost completely restored when the crosslinks were 
broken by subsequently treating proteoliposomes with 1 mM DTT after HgCl2 removal (again, on both 
sides of the membrane), indicating that the abolition of transport was caused by disulfide bond 
formation. In addition, recovery of full transport activity demonstrates that HgCl2 treatment does not 
irreversibly damage the protein or the lipid bilayer. Similarly, crosslinking the reconstituted inward-
stabilizing mutant also reversibly abolished transport activity (Supplementary Fig. 5c). Crosslinking the 
purified mutant proteins prior to reconstitution also led to full inhibition of transport, as did CuPhen-
mediated crosslinking, demonstrating the robustness of crosslink formation (data not shown). Cysless 
VcINDY retained the bulk of its transport activity (~60%) upon treatment with crosslinking reagent, again 
fully reversible on reduction (Fig. 5). This minor activity loss suggests, as others have reported for 
different transporters24, that HgCl2 can either interact with the protein in positions other than the 
cysteine residues or that the crosslinking reagent interacts with the lipid bilayer and compromises its 
integrity. In our case, however, the retention of substantial transport activity in the HgCl2-treated Cysless 
protein confirms that the strong inhibition in the crosslinked proteins is due to the specific effects of the 
crosslinking agents on the double cysteine mutants. Together these results strongly support our 
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hypothesis that the large conformational change required to form the crosslinks is also an essential 
component of the transport process. 
 
The dimer interface remains relatively rigid during transport 
The data described so far demonstrate large-scale conformational changes between helices in 
the scaffold and helices in the transport domain. In constructing a model of the outward-facing dimer, as 
described above, we made the assumption that the helices contributing to the oligomerization interface 
(i.e., from the scaffold), would remain fixed relative to one another. We tested this assumption by 
assessing the functional effects of “stapling” the protomers together at several inter-protomer contact 
points. Thus, if substantial conformational changes at the dimer interface are essential for transport then 
stapling the protein at these positions should abolish transport activity. 
According to the inward-facing crystal structure, the VcINDY dimer contains four inter-protomer 
contact points: TM helices 8 and 4b from one protomer interact with TM helix 3 and interfacial helix 4a 
from the other protomer, respectively; and helix 4a and TM helix 9b in one protomer interact with their 
counterparts in the other protomer (Fig. 6a). We introduced cysteine pairs into the dimer interface at 
these 4 contact points; Q86C (helix 4a)/S95C (TM4b), V68C (TM3)/S304C (TM8), N90C (helix 4a), and 
K316C (TM9). Due to the two-fold symmetry of the VcINDY homodimer, we expected the mutants 
containing two cysteine residues per protomer to form two disulfide bonds across the interface, whereas 
we expected the corresponding single cysteine mutants to form single disulfide bonds (with their 
symmetry-related counterparts). Each interfacial cysteine mutant was stable and exhibited robust 
transport activity when reconstituted into liposomes (Fig. 6 and Supplementary Fig. 6). 
The inter-protomer crosslinks formed readily upon incubation with CuPhen, which we assessed 
by running the proteins on non-reducing SDS-PAGE gels; a shift of the protein band from the monomeric 
VcINDY molecular weight to that expected for the dimer indicates crosslinks formation (Fig. 6b, “D”). 
Purifying and then maintaining the mutants in reducing conditions completely prevented crosslink 
formation (Fig. 6b). Importantly for our functional assays, crosslinks remain stable during reconstitution 
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of the treated protein into liposomes, as ascertained by Western blot analysis (Fig. 6b “PL”). Incubation 
with 10 μM 2:1 CuPhen for 45 minutes at room temperature fully crosslinked all proteins except for the 
V68C/S304C mutant. V68C/S304C required 500 PM CuPhen to attain full crosslinking, which presumably 
reflects reduced accessibility of these residues to the crosslinking agent or sub-optimal alignment of the 
two cysteines. 
We evaluated the transport competence of the crosslinked proteins by measuring Na+-driven 
succinate uptake (Fig. 6c). All four “stapled” mutants exhibited robust transport activity after crosslink 
formation, demonstrating that there are no substantial conformational changes in these positions that 
are essential for transport (Fig. 6c). However, upon closer analysis, the functional effects of stapling the 
dimer interface varied depending on the position of the disulfide crosslink. Crosslinking two of the 
mutants, V68C/S304C and N90C, had no discernable effect on their transport activity beyond the non-
specific effects we observed for Cysless (Fig. 6c). Interestingly, however, crosslinking the other two 
mutants, Q86C/S95C and K316C, resulted in a 5-fold and 2-fold transport activity decrease, respectively. 
It is difficult to delineate from our current data why constraining the protein in these positions causes 
this inhibition. One possibility is that the cross-linking causes a local distortion in the scaffold domain 
that reduces the ability of the transport domain to move along it. Nevertheless, unlike the crosslinks 
between scaffold and transport domain, all of these crosslinks preserve at least partial transport activity. 
Further studies will be necessary to illuminate the underlying causes of these more subtle effects. As we 
found with HgCl2, treating cysteine-free VcINDY with 0.5 mM CuPhen reduced the activity to ~60% 
compared to the untreated sample. In contrast, we observed no change in activity for Cysless upon 
treatment with 10 PM CuPhen (Fig. 6c). Cysteine-independent effects of CuPhen have been observed 
previously with proteoliposomes and membrane vesicles and have been attributed to Cu2+ binding 





In this study, we present a structural model of the outward-facing state of VcINDY along with extensive 
experimental data supporting this model. This work demonstrates that VcINDY utilizes an elevator-type 
movement, with protein excursions on the order of 	?15 Å, that is an essential step in the transport cycle. 
Our conclusions are based on the formation of disulfide crosslinks between cysteine pairs introduced in 
three different locations, each physically separated in the inward-facing structure, but predicted by our 
model to be juxtaposed in the outward-facing state. That these crosslinks form readily shows that the 
protein can adopt the predicted outward-facing conformation; that they profoundly disrupt transport 
confirms that movement to and from this state is essential for transport. Moreover, preservation of 
transport activity in the presence of crosslinks across the dimer interface reveals that no major 
conformational change in this region is required for transport.  
Repeat-swap modeling provides access to structures not otherwise available 
Due to the dynamic nature of secondary transport, our understanding of their mechanism 
requires knowledge of multiple conformational states during the transport cycle. To obtain alternate 
conformations at useful resolutions, X-ray crystallography is the usual method of choice, although often 
results in the same conformation being trapped despite significant efforts to obtain different states. In 
this study, we demonstrate the power of an elegant modeling approach, based on the internal 
asymmetry found in the known structure of VcINDY, to predict alternate protein conformations, 
combined with extensive experimental evaluation. Internal asymmetry has been used to predict 
alternate conformations of members of several different transporter families, demonstrating that 
proteins with inverted-topology repeats conform to a strategy of asymmetry exchange, and providing 
testable, atomistic models for several different proteins with distinct folds12,21,22. Approximately three-
quarters of all secondary transporters contain such internal symmetry, making this approach a viable 
option in the pursuit of mechanistic understanding on a broad scale26. 
As repeat-swap modeling is, in essence, a homology modeling technique, the error of the model 
depends on the difference in the sequences of the two repeats, which in the case of VcINDY is ~20%, 
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implying a structural error of 1-3 Å in the CD positions27. However, our updated protocol reduces this 
error significantly, by including a second refinement step that effectively maintains the integrity of the 
domains moving relative to one another, while preserving the overall movement of those domains (see 
Methods; Supplementary Figs. 2 and 7). Overall this new strategy, and the success of the method on 
previous occasions, gives confidence that the overall conformational change predicted will be correct.  
Comparison of the inward-facing state captured in the crystal structure of VcINDY with our 
outward-facing model, suggests that the transport domain moves vertically ~15 Å and rotates 43o, 
thereby translocating the substrate binding site to the other side of the hydrophobic barrier provided by 
TM helices 4 and 9. The extent to which the degree of this conformational change is representative of the 
true mechanism depends on the known structure. If the excursion of the transport domain in the 
template is large, i.e., because the asymmetry between the repeats is significant, then the excursion of 
the transport domain in the model will be equivalently large; as a consequence, the comparison 
between the model and structure will predict a more substantial conformational change. Insofar, 
though, as the X-ray structure of VcINDY accurately represents the inward-facing state (despite being 
bound to an inhibitor18 rather than a transported substrate), the model should also represent the 
outward-facing state. The success of our experimental test of the model, with multiple successful 
crosslinks representing the outward-facing state, strongly suggests that the modeled conformation 
represents a native state, and that the conformational change is truly elevator-like.  
The crosslinked protein represents a native conformation of VcINDY 
A key assumption underlying our results is that the states stabilized by our crosslinks represent 
well-populated conformations accessible to the native protein rather than rarely-visited grotesques that 
have been kinetically trapped by the disulfide bond. We report crosslinks between three different 
cysteine pairs, distributed across the transport/scaffold domain interface. This combination of 
appositions would be extraordinarily difficult to achieve with a fundamentally different conformational 
change. Moreover, the wide range of conditions used in these experiments, including crosslink 
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formation using either CuPhen or HgCl2 with protein in either detergent or lipid membranes, argues that 
we are sampling a native state of the protein. In addition, the consistent mobility of the crosslinked 
protein on size exclusion chromatography rules out the possibility of a reversibly denatured form of the 
protein that is stabilized by the crosslink. 
The work described here was made more difficult by the sensitivity of VcINDY to modification, 
particularly at the interface between the transport domain and the scaffold domain. Single point 
mutations were sufficient to completely destabilize the protein. This apparent sensitivity is in stark 
contrast to the situation with GltPh, which tolerated extensive modification. Is there an obvious reason for 
this difference in sensitivity? Comparison of the interfaces of the two proteins demonstrates that the 
surface of the transport domain that is predicted to slide against the scaffold domain in VcINDY contains 
70% apolar amino acids; this patch of hydrophobic residues is significantly larger than in GltPh, where 
only 46% of the residues are apolar. The additional hydrophobicity in the interface may not have 
tolerated oxidized cysteine. 
Other Transporters with Proposed Elevator-Type Mechanisms 
How does the movement of VcINDY compare with other proposed elevator-type transporters? 
Currently, the only transporter that can indisputably be called an elevator-type transporter is the 
glutamate transporter homolog, GltPh13,28. Our results demonstrate that the transport domain of VcINDY 
undergoes a similar perpendicular and rotational movement to that of GltPh (~15 Å and 43o for VcINDY vs. 
16 Å and 37o for GltPh)13.  
Recently, it has been suggested that members of the cation-proton antiporter (CPA) family, 
exemplified by the Na+/H+ exchanger NhaA, employ an elevator-type mechanism, although this remains 
controversial. The CPA fold consists of a transport domain containing two unwound helices that cross in 
the middle of the membrane to form substrate binding sites. An experimentally-validated symmetry-
based model along with normal mode analysis of a structure of E. coli NhaA suggest that a panel of four 
TM helices in NhaA may rotate within the plane of the membrane and around the transport domain in 
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order to open and close the inward and outward-facing pathways23. However, upon elucidation of the 
structure of NapA, a remote NhaA homolog, and subsequent structural comparison with NhaA, it has 
been argued that substrate-binding residues in NapA move 10 Å in the membrane, consistent with an 
elevator-type movement14. A caveat here is that NapA shares <15% identical residues with NhaA, making 
any conclusions drawn from the direct comparison of the two proteins somewhat tenuous. More 
recently, and contrary to the conclusions drawn from the NapA structure, structural analysis of two other 
CPA family members, PaNhaP and MjNhaP1, both solved in two conformations, suggest that only slight 
conformational changes are required for transport29,30. The structure of a bacterial concentrative 
nucleoside transporter, VcCNT, also reveals the hallmarks of an elevator-type transporter, although its 
structure has so far only been captured in an inward-facing state31,32. Interestingly, repeat-swap modeling 
predicts an elevator-type movement for this protein (Vergara-Jaque, Fenollar-Ferrer, Kaufmann and 
Forrest, under review) though this prediction has not yet been experimentally tested. 
Common features of elevator-type transporters 
Several shared structural features are immediately apparent upon looking at the structures of 
GltPh, VcINDY and VcCNT. All three transporters have similar overall architecture, with a scaffold domain 
wrapped around a transport domain, and all are oligomers (VcINDY is a dimer, GltPh and VcCNT are 
trimers), possibly to aid in stabilization. In all three cases, the transport domain contains two re-entrant 
hairpin loops that dip into the membrane but do not cross it: the tips of these re-entrant loops 
coordinate substrates in all three transporters. Finally, all three folds contain a broken helix whose two 
segments are connected through an intramembrane loop (helices 5 and 10 in VcINDY, see Fig. 2a) that 
also contributes to the substrate-binding region.  
Seemingly, a major mechanistic difference between GltPh and VcINDY is that in GltPh the re-entrant 
hairpin loops act as inner and outer gates that cover the substrate binding site and regulate substrate 
binding/release. In both the inward-facing structure and the outward-facing model of VcINDY, the 
substrate is almost completely solvent exposed (Fig. 2), obviating the need for such gate movement. 
17 
However, the electron density in the VcINDY crystal structure is ascribed to citrate, which is, in fact, a low 
affinity inhibitor16. Thus, our current analysis of the inhibitor-bound structure/model may miss some 
more subtle structural changes, for example, gate movement. Structural data for substrate-bound 
VcINDY will be required to uncover such details. 
How widespread is the elevator-type mechanism? 
Recent reports provide evidence that several transporter families have essentially the same fold 
as VcINDY. These transporters include the human Na+/Pi transporter, NaPi33; and two recently structurally 
characterized representatives from the p-aminobenzoyl-glutamate transporter (AbgT) family, YdaH and 
MtrF34,35. The DASS family, to which VcINDY belongs, and the AbgT family, have both been assigned to 
the Ion Transporter (IT) superfamily, begging the tantalizing question; is the elevator-type movement a 
common mechanism for all IT superfamily members? Obviously, the mechanism underlying transport by 
the other IT superfamily members must be investigated, but the commonality of this architecture hints 
at widespread use of this mechanism. 
Mammalian homologs of VcINDY are potential drug targets in the treatment of metabolic 
diseases, age-related diabetes and obesity15,36. VcINDY is ~30% identical and shares a number of 
functional characteristics, such as substrate specificity and coupling ion stoichiometry, with its 
mammalian homologs, in particular hNaDC316. In addition, both VcINDY and hNaDC3 are allosterically 
inhibited by the anthranilic acid derivative, flufenamic acid, which is thought to interact at the interface 
between the scaffold and the transport domain16,37,38. These fundamental mechanistic similarities 
strongly suggest that the overall architecture and basic mechanism of transport are similar in all 
members of the DASS family. By extension, it would appear that the elevator-type motion is also an 
essential part of the transport cycle in the mammalian counterparts. Further work is required to explicitly 
demonstrate a shared structural mechanism for this family of transporters. 
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What is the advantage of an elevator mechanism? 
Why would the elevator-type mechanism be favored over other transport mechanisms such as, 
say a “rocking bundle” mechanism? One apparently common characteristic of several potential elevator-
type transporters is the tendency to couple substrate transport to multiple (≥3) coupling ions. At 
equilibrium, increasing the number of coupling ions (n) dramatically increases the capacity for substrate 
accumulation, with this increase changing as the nth power of the ion gradient. An elevator mechanism 
might be a useful way to insulate the transporter from back-leak of substrate or coupling ions, since it 
can never contain a continuous return path. Increasing the prevalence of well-studied elevator 




A VcINDY outward-facing model was obtained by applying the repeat-swapped homology 
modeling technique following a recently revised protocol (Vergara-Jaque, Fenollar-Ferrer, Kaufmann and 
Forrest, under review). The repeats in the VcINDY structure, PDB ID: 4F3518, were defined as comprising 
residues 42-242 for repeat unit 1 (RU1) and 253-462 for repeat unit 2 (RU2). The analysis of the symmetry 
axis of the repeats was performed using SymD39. TM-align was used to structurally superimpose these 
repeats40, and to build an initial sequence alignment of the template and the model sequences. This 
initial alignment was refined by removing gaps within secondary structural elements (obtained from 
DSSP41,42) and by using conservation scores (obtained from the ConSurf server with default settings43) to 
position conserved residues so that they were preferentially oriented toward the inside of the protein 
For each refinement step, 200 iterations of restraint optimization were performed using Modeller v9.1344. 
Each set of models was evaluated using MolPDF and ProQM45 scores as well as Procheck analysis45,46.  
The refined, final alignment was then used to generate a set of 2000 repeat-swapped 3D models 
of which the best model was selected as that which best met the following criteria: the lowest MolPDF 
score, the highest global ProQM scores, and the most residues in favored regions of the Ramachandran 
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plot. This model was then used to identify the scaffold and transport domains, which were assigned as 
residues 19-126 plus 253-356, and 127-242 plus 357-462, respectively. Final refinement of the model 
involved adding distance restraints between Cα atoms taken from the known structure in addition to 
those necessary to position the ions and bound ligand in the binding site. Distance restraints between 
Cα atoms were assigned according to the input crystal structure for all pairs of Cα atoms <60 Å apart 
within either the transport or scaffold domains in the template structure, PDB ID: 4F3518. We note that 
these intradomain restraints did not alter the extent of the conformational movement, but maintained 
the internal arrangement of the two domains (Supplementary Figs. 2b and 7). Distance restraints were 
also applied in the substrate binding sites: between the Na+ ion and the O atoms in the backbone of 
S146, S150 and N199, the hydroxyl group of S146 and the amide group of N151; and between any non-
hydrogen atoms of the citrate and the protein within 3.5 Å in the template structure. All applied distance 
restraints were represented as Gaussians with a standard deviation of 0.1 Å. Using these restraints, a new 
set of 2000 models was generated using Modeller, and again the final model was chosen using the 
criteria mentioned above. 
The orientation of the VcINDY X-ray structure in the membrane was determined with the OPM 
server47, while the orientation of the model was defined after superposition of the scaffold domain onto 
the crystal structure.For the analysis of the transport-scaffold interface, we selected all residues with any 
atom within 5 Å of the other domain in either inward- or outward-facing conformation. In the case of 
GltPh PDB entries 3KBC (inward-facing) and 1XFH (outward-facing) were used. All molecular figures and 
movies were generated using PyMOL v1.6 (Schrödinger, Ltd) unless stated otherwise. The final model is 
provided as Supplementary Data. 
 
Molecular biology 
All mutants were made using the Quikchange II site directed mutagenesis kit (Agilent 
Technologies) and were fully sequenced to ensure sequence fidelity. All cysteine mutants were 
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generated in cysteine-free background where all three native cysteines in VcINDY were substituted for 
serine.  
Protein expression and purification 
VcINDY and its variants were expressed and purified as detailed previously18. VcINDY was 
expressed in Escherichia coli BL21-AI cells (Life Technologies) from a modified pET vector in frame with a 
N-terminal decahistidine tag48. Cells were grown in LB supplemented with 30 ug/ml kanamycin at 37oC 
until they reached an A600 of 0.8, at which point they were rapidly cooled to 19oC in an ice bath. 
Expression was induced by addition of IPTG and L-arabinose to final concentrations of 10 PM and 6.6 
mM, respectively. Cells were incubated overnight at 19oC. Cells were harvested and resuspended in Lysis 
Buffer (50 mM Tris, pH 8, 400 mM NaCl and 20% glycerol), and lysed using a homogenizer (Emulsiflex-C3, 
Avestin). The membrane fraction was isolated by ultracentrifugation, resuspended in Purification Buffer 
(50 mM Tris, pH 8, 200 mM NaCl and 10% glycerol), and solubilized by addition of n-dodecyl-β-D-
maltoside (DDM, Anatrace) to a final concentration of 20 mM. Residual insoluble material was removed 
by ultracentrifugation and the soluble fraction was incubated with Talon metal affinity resin (Takara Bio 
Inc.) overnight at 4oC. Resin was washed by consecutive additions of 20 column volumes-worth of 10 mM 
and 20 mM imidazole-containing Purification Buffer supplemented with 2 mM DDM. Bound protein was 
eluted whilst simultaneously cleaving the affinity tag by incubating the resin with Purification Buffer 
supplemented with 2 mM DDM and 10 Pg/ml trypsin at 4oC for 1 hour. The flowthrough from the column 
was collected, concentrated and further purified using a Superdex 200 size exclusion chromatography 
(SEC) column (GE Healthcare) equilibrated with SEC buffer (25 mM Tris pH, 100 mM NaCl, 5% glycerol and 
3 % n-decyl-E-D-maltoside (DM)). For the dimer interface mutants, protein was eluted from the Talon 
resin by addition of Purification Buffer supplemented with 300 mM imidazole. The affinity tag was 
maintained for identification of the protein using Western blotting. The dimer interface mutants were 
then desalted into SEC buffer using Zeba Spin desalting columns (Life Technologies). Purified protein 
was concentrated, snap frozen and stored at -80oC. All proteins were purified using buffers containing 
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either 0.5 mM tris(2-carboxyethyl)phosphine (TCEP) or 1 mM dithiothreitol (DTT) to keep the cysteines 
reduced. 
Reconstitution 
The functional reconstitution of protein into liposomes was performed as detailed previously49. 
25-100 Pg of purified protein was diluted to 2 ml in SEC buffer (with 1 mM DTT, if required) and mixed 
with 400 Pl 20 mg/ml lipids, which consisted of a 3:1 mixture of E. coli polar lipids and POPC (Avanti Polar 
Lipids, Inc). The protein/lipid mixture was incubated on ice for 10 min and then rapidly diluted into 65 ml 
Inside Solution containing 20 mM Tris/HEPES, pH 7.5, 1 mM NaCl, 199 mM KCl and 0.5 mM TCEP/1 mM 
DTT, where required. Proteoliposomes were collected by ultracentrifugation and resuspended in Inside 
Solution to a concentration of 8 mg/ml lipid. Proteoliposomes were freeze-thawed 3 times and stored at 
-80oC or used immediately. After this point, the internal solution was modified by collecting the 
proteoliposomes by centrifugation, resuspending them in the desired solution, freeze-thawing 3 times 
and extruding. 
In vitro transport assays 
Proteoliposomes were prepared for transport assays by extruding them through a 400 nm filter 
11 times and concentrating them to 80 mg/ml lipid using ultracentrifugation. The transport assays were 
started by adding the proteoliposomes to Reaction Buffer (20 mM Tris/HEPES, pH 7.5, 100 mM NaCl, 100 
mM KCl, 1 μM valinomycin, 1 μM [3H]-succinic acid (American Radiolabeled Chemicals). At the indicated 
times, samples were taken and the reaction was terminated by adding the sample to ice cold Quench 
buffer (20 mM Tris/HEPES, pH 7.5, 200 mM ChCl) and rapidly filtering the sample through a 200 nm 
nitrocellulose filter (Millipore). The filter was washed with 3 ml Quench buffer, the filters were dissolved 
in FilterCount liquid scintillation cocktail (PerkinElmer) and the [3H]-succinic acid internalized by the 
proteoliposomes was counted using a Trilux beta counter (PerkinElmer). 
Protein crosslinking and PEGylation assay 
To induce disulfide bond formation, the proteins were exchanged into Conjugation Buffer (50 
mM Tris, pH 7, 100 mM NaCl, 5 % glycerol, and 3% (w/v) DM) to remove the reducing agent and then 
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incubated with 5-fold molar excess of HgCl2 or freshly prepared solution of copper phenanthroline 
(CuPhen). A 2:1 ratio of CuPhen was prepared by mixing solutions of 500 mM 1,10-phenanthroline and 
250 mM CuSO4. The final CuPhen concentration ranged from 10 to 500 PM depending on the particular 
cysteine mutant. Regardless of which crosslinking reagent was being used, the crosslinking reaction was 
incubated at room temperature for 45 min. Control samples were treated identically except were 
incubated in the presence of 0.5 mM TCEP or 1 mM DTT. 
Protein Digestion and Mass Spectrometry 
Protein samples, at 10 PM, in 50 mM Tris pH 7, 150 mM NaCl, 5% glycerol, 0.1% DM were either 
reduced with 1 mM DTT (‘R’) or treated with 100 PM or 500 PM CuPhen to induce disulfide formation (‘X’) 
followed by desalting to remove the reagent. ~5 μg of protein was alkylated by incubation with 10 mM 
N-ethylmaleimide (NEM, Sigma) for 20 min at room temperature. A120C/V165C was digested with 500 
ng trypsin for 8 hr at 37oC and further digested with 300 ng chymotrypsin (Roche, Indianapolis, IN) for 8 
hr at 25oC ; T154C/V272C was digested with 600 ng chymotrypsin at 25oC overnight. The digests were 
cleaned with an HLB PElution plate (Waters, Milford, MA). The LC/MS/MS experiments were performed 
on an Orbitrap Elite mass spectrometer (Thermo Scientific) connected to a 3000 RSLC nano HPLC system 
with an RS auto-sampler (Thermo-Dionex) via an Easy-Spray ion source (Thermo Scientific). 
Approximately 1 μg of digested protein was injected onto an ES802 Easy-Spray column (25cm x 75μm ID, 
PepMap RSLC C18 2μm; Thermo Scientific) and then separated at a flow rate of 300 nl/min with a 38 min 
linear gradient of 2–30% mobile phase B (mobile phase A: 2% acetonitrile, 0.1% formic acid; mobile 
phase B: 98% acetonitrile, 0.1% formic acid).  
The Orbitrap Elite was operated in a decision tree mode. The precursor ion scan was performed in 
the Orbitrap with a resolution of 60K at m/z 400. The m/z range for survey scans was 300–1600. The 
fragment ion scan was performed in the linear ion trap. The minimum signal threshold for MS/MS scan 
was set to 3 x 104, and up to 10 MS/MS scans were performed after each MS scan. A 9 sec dynamic 
exclusion window was selected with early expiration enabled.  
Peptide Identification 
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Mascot Distiller (version 2.5.1.0) was used to convert the Xcalibur Raw data to peak list file in mgf 
format. Mascot Daemon 2.4.0 was used to submit the MGF files to Mascot Server 2.4 for the database 
search. Data were searched against a house-built database that contains the sequences of NCBI human 
database and the sequences of 120/165-R, 120/165-X, 154/272-R and 154/272-X. The following 
parameters were included in the search: Peptide tolerance, ± 10 ppm; MS/MS tolerance, 0.2 Da; 
Instrument type, CID+ETD; Enzyme, None; Missed cleavage, 0; Variable modification, Oxidation (M) and 
NEM (C). Once a peptide (Px) containing a Cys residue was detected, a 2nd database search was 
performed assuming Px-2H (the mass of Px minus 2 hydrogen atoms) as a potential modification. Once a 
plausible cross-linked candidate was found in the 2nd search, the MS/MS spectrum of that candidate was 
manually checked. A potentially cross-linked candidate was considered real if the following conditions 
were satisfied: 1) Major peaks of the MS/MS spectrum of the cross-linked candidate could be assigned 
manually; 2) The candidate was only detected in the X samples, not in the corresponding R samples.  
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Supplementary Movie 1: Predicted transport-associated conformational change in VcINDY. 
The conformational change predicted for VcINDY is modeled by morphing the VcINDY inward-facing X-
ray structure (PDB ID: 4F35) (start) with the repeat-swapped model of the outward-facing conformation 
(end point). The interpolation between structure and model was done using the Morph250. VcINDY is 
represented as cartoon helices and the coloring scheme reflects the division between scaffold (blues), 
oligomerization domain (dark blue) and transport domain (orange), as shown in Figure 1. The sodium ion 
and the citrate are shown as purple and yellow spheres, respectively. The protein is viewed from the 
plane of the membrane, first, from the perspective of the other protomer, and secondly, along the dimer 
axis.  
 
Supplementary Movie 2: Cross-linking during the transport-associated conformational 
change in VcINDY. See legend to Supplementary Movie 1 for more detail. Here, the CD atom of each of 
the residue pairs that crosslink in the outward-facing conformation is also shown as spheres, color-coded 
by crosslinking pair as follows: Ala120 and Val165 in magenta, Thr154 and Val272 in green and Ala346 
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